Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs iShares MBS ETF (MBB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs iShares MBS ETF — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $106.81 (market cap $8.88B), while iShares MBS ETF trades at $89.99 (market cap $35.76B). The key difference: iShares MBS ETF is far larger — about 4× Kymera Therapeutics Inc. Common Stock's market cap, and Kymera Therapeutics Inc. Common Stock is trading nearer its 52-week high, iShares MBS ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and iShares MBS ETF for 97 Days on average.
| KYMR | MBB | |
|---|---|---|
Market Cap | $8.88B | $35.76B |
Volume | 1,028,790 | 19,694,940 |
Sector | Health | Fixed Income |
52-Week High | $127.31 | $96.91 |
52-Week Low | $55.80 | $89.09 |
Typical Hold Time | 0 Days | 97 Days |
Enterprise Value | $8.27B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
MBB (iShares MBS ETF) trades at $89.97 with minimal daily movement (+0.16%). The technical outlook is bearish with moving averages and oscillators signaling caution, though the stock shows strong institutional interest despite recent short interest growth. Recent news highlights Norway's sovereign wealth fund rotating into mortgage-backed securities, providing sector validation.
The ETF faces headwinds from rising intermediate-term rates and convexity risk, limiting upside potential. While dividend payments provide income, the bearish technical setup and interest rate sensitivity suggest cautious positioning. Institutional accumulation contrasts with growing short interest, creating mixed signals for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About iShares MBS ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index and TBAs that have economic characteristics that are substantially identical to the economic characteristics of the component securities of the index, and the fund will invest at least 90% of its assets in fixed income securities included in the underlying index that advisor believes will help the fund track the index.
Read more on MBB →
